Atlas Trials

SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer

Clinical trial NCT06340230 · RECRUITING

Trial details

NCT number
NCT06340230
Sponsor
Shengjing Hospital
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
HR Positive/HER2 Low Breast Cancer
Start date
2024-08-23
Primary completion
2026-02-28
Enrollment
93

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.